Latest

0002S 0010 Takingstock Header1
  • Market commentary
  • 06 Oct 2025
  • 6 reading min

AbbVie slashes 2024 EPS forecast on $2.7bn R&D charge, warns results may vary

In today's Taking Stock, AbbVie cut its 2024 adjusted EPS forecast to $10.38–$10.58, citing a $2.7 billion Q3 charge related to in-process R&D, well below analyst consensus of $12.02.

By Research Team
0002S 0005 Takingstock Header6
  • Market commentary
  • 03 Oct 2025
  • 6 reading min
Embraer deliveries rise 5% in Q3, shares slide 5.8% ahead of results
By Research Team
0002S 0008 Takingstock Header3
  • Market commentary
  • 02 Oct 2025
  • 6 reading min
Tesla poised for strongest 2025 quarter as U.S. demand spikes before EV tax credit expires
By Research Team
0002S 0009 Takingstock Header2
  • Market commentary
  • 01 Oct 2025
  • 7 reading min
CoreWeave Lands $14.2bn Meta Deal, Fuelling AI Infrastructure Boom
By Research Team

Offcanvas Title

Default content goes here.
Intro